Production of a medicinal product – a mini-inhaler for the treatment of influenza, COVID-19, and acute respiratory viral infections (ARVI) in Russia.
Organization of production and additional post-registration clinical trials of the mini-inhaler based on aprotinin for the treatment and prevention of viral lung diseases.
Biotechnology And National Health
Technologies for human health
Implementation Stage (import substitution of a Czech manufacturer). The product has all the necessary approvals from government authorities for sale in the Russian Federation and was sold in all pharmacies across Russia for five years (from 2012 to 2018).
The project will be implemented across the Russian Federation, with initial production and distribution focused on key regional markets. The product will be distributed through a network of wholesale pharmaceutical distributors and pharmacy chains that cover both urban and rural areas.
For 30 years, the antiviral aerosol "Aerus" (now renamed "Antiprovir") has been developed. After completing the cycle of clinical trials from 1994 to 2004, Patent No. 2425691 was obtained. In 2009, the company submitted documentation to the Ministry of Health of Russia and received Registration Certificate No. LSR-000280/10. Since 2012, the drug has been supplied to Russia, particularly to the Ministry of Defense of Russia under a contract. In 2023, the drug "Aerus" was included among the priority Russian developments and was presented as an innovative drug at the BRICS summit. Production is now approved at the "Altaivitamins" plant, and a pilot batch of the medicine has been produced.
N.A.
N.A.
